Sialic acid derivatives for protein derivatisation and conjugation
Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
1. A process for producing an aldehyde derivative of a reducing terminal sialic acid of a di-, oligo- or poly-saccharide that has a non-reducing terminal saccharide that contains a vicinal diol group, which process comprises:
a) oxidizing said vicinal diol group of the non-reducing terminal saccharide to an aldehyde;
b) reducing the reducing terminal sialic acid unit and the aldehyde formed in a) to effect ring opening of the reducing terminal sialic acid, whereby a vicinal diol group is formed at the reducing terminal sialic acid and the aldehyde formed in step a) is also reduced to a hydroxy group; and
c) oxidizing the vicinal diol group formed in step b) to obtain a product comprising an aldehyde at the reducing terminal.
2. The process of claim 1 wherein the reducing terminal is sialic acid joined to the saccharide through the 8 carbon atom.
3. The process of claim 1 wherein the saccharide unit at the non-reducing end is a sialic acid unit.
4. The process of claim 1 wherein the polysaccharide is a polysialic acid consisting of sialic acid units.
5. The process of claim 4 wherein the polysaccharide has at least 5 sialic acid units.
6. The process of claim 1 wherein step a) is carried out under conditions that do not result in mid-chain cleavage of the polysaccharide.
7. The process of claim 6 wherein step a) is carried out in aqueous solution in the presence of periodate at a concentration in the range 1 mM to 1M, a pH in the range 3 to 10, a temperature in the range 0 to 60° C. and a time in the range 1 min to 48 hours.
8. The process of claim 1 wherein step b) is carried out under conditions such that pendent carboxyl groups on the starting material are not reduced.
9. The process of claim 8 in which step b) is carried out in aqueous solution in the presence of borohydride at a concentration in the range 1 μM to 0.1M, a pH in the range 6.5 to 10, a temperature in the range 0 to 60° C. and a period in the range 1 min to 48 h.
10. The process of claim 1 which further comprises reacting the product of step c) with a substrate having a primary amine group or a hydrazide group whereby the aldehyde group reacts with the primary amine or hydrazide group to form a conjugate product, comprising a C═N bond.
11. The process of claim 10 which further comprises reducing the C═N bond to a C—N bond.
12. The process of claim 10 wherein the substrate is a peptide or a protein.
13. The process of claim 12 wherein the substrate is a peptide therapeutic.
14. The process of claim 10 wherein the substrate comprises an additional functional group linked through a divalent linker to the amine or hydrazide group.
15. The process of claim 10 wherein the substrate is a drug delivery system, a cell, a virus or a synthetic polymer.
16. An activated or conjugated di-, oligo or polysaccharide having a sialic acid residue at the reducing terminus,
wherein said sialic acid at the reducing terminus has been converted to OX wherein X is
CH 2 CHO, CH 2 CHNR 1 , —CH 2 CH 2 NHR 1 , CH 2 CH═N—NHR 1 , or CH 2 CH 2 NHNHR 1 in which R 1 is H, C 1-24 -alkyl, aryl C 2-6 -alkanoyl, or a polypeptide or a protein linked through the N terminal or the γ-amine group of a lysine residue thereof, a drug delivery system or is an organic group having a functional substituent adapted for reaction with a sulfhydryl group, and
wherein said di-, oligo-, or polysaccharide lacks a vicinal diol or aldehyde group at the non-reducing terminal unit.
17. The compound of claim 16 of the formula
wherein n is 1 or an integer, each GlyO is a glycosyl group which may be the same or different, and X is
CH 2 CHO, CH 2 CHNR 1 , —CH 2 CH 2 NHR 1 , CH 2 CH═N—NHR 1 or CH 2 CH 2 NHNHR 1 wherein R 1 is as defined in claim 16 .
18. The compound of claim 17 wherein substantially all the GlyO groups are sialic acid groups, joined 2-8, 2-9 or alternating 2-8/2-9, to one another.
19. The compound of claim 18 wherein n is at least 5.
20. The compound of claim 16 wherein R 1 is a protein or peptide or a drug delivery system.
21. The compound of claim 16 wherein X is
22. The compound of claim 16 wherein X is
23. The compound of claim 19 or claim 22 wherein R 1 is a peptide or protein therapeutic.
24. The compound of claim 16 wherein R 1 is
wherein R 2 is C 2-12 -alkylene group.
25. A composition comprising a compound of claim 16 and a diluent.
26. A pharmaceutical composition comprising a compound of claim 19 and a pharmaceutically acceptable excipient.